

Mr Olivier Legrain, Chief Executive Officer of IBA, commented: "We are delighted to collaborate with Parkway Pantai, one of the largest integrated private healthcare groups in Asia. This collaboration further increases the reach of proton therapy around the world and demonstrates IBA's superior product offering in the market. Our ProteusONE solution is a unique truly compact intensity modulated proton therapy (IMPT) system and, alongside its open gantry and track record of short installation time, is the solution of choice for an increasing number of hospitals globally. We look forward to collaborating with Parkway Pantai to provide greater access to proton therapy for cancer patients in Singapore and the South East Asia region."

Dr Tan See Leng, Group Chief Executive Officer and Managing Director of Parkway Pantai, commented: "This is the largest single investment in medical technology that Parkway Pantai has made to date. It will revolutionise the way cancer is treated in this region. This new proton therapy centre will be the first of its kind among private hospitals in South East Asia. It underscores our commitment to provide patients with the best possible treatment options. Construction of the new facility will begin in early 2019. Our patients in Singapore and the region will now have easy access to better care when the centre opens in 2021. We expect this new capability to enhance Singapore's position as a healthcare leader in the region."